A major data real world study of apatinib in the treatment of gastric cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017662

Enrollment

Unknown

Registered

2018-08-08

Start date

2018-08-08

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Case series:apatinib

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged at least 18 years; 2. Have failed for at least 2 lines of chemotherapy or Recurrent advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma; 3. Doctors believe that treatment can benefit patients; 4. Participants were willing to join in this study, and written informed consent.

Exclusion criteria

Exclusion criteria: 1. It has been confirmed that allergic to apatinib tablets and/or their excipients; 2. Pregnant or lactating women; 3. Patients with contraindications to apatinib; 4. The researchers think inappropriate.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
Progression free survival;Overall survival;2. Objective response rate ;Disease control rate;	—

Countries

China

Contacts

Public ContactLi Yong

Fourth Hospital of Hebei Medical University

li_yong_hbth@126.com+86 13931116966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026